**Curebound Letter of Intent**

Letters of Intent will be reviewed by the Curebound Scientific Advisory Board and Staff. They will be used to determine eligibility, alignment with one or more of Curebound’s Scientific Pillars, and to inform the peer review process. Selected applicants will be notified via email by June 12, 2023 and invited to submit a full application byTuesday August 1, 2023.

**Applicants must submit an LOI to be invited to submit a full application and be considered for Curebound funding.**

1. Team Leader

|  |  |  |  |
| --- | --- | --- | --- |
| **Name** | **Title** | **Institute** | **Email address** |
|  |  |  |  |

1. Co-PIs and Key Collaborators

*May be added later for Discovery Grants, Targeted Grants, and Cure Prize. The Discovery Grant full application must have an inter-institutional collaboration.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Name** | **Title** | **Institute** | **Email address** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

1. Tentative Title

*Proposal title can be changed on submission of full application.*

|  |
| --- |
|  |

1. Award Type

*A Team Leader may submit one LOI for each award type. Please indicate which award type this LOI is for. (Pick one)*

|  |  |
| --- | --- |
| Discovery Grant: Up to $250,000 inclusive of IDC /1 year |  |
| Targeted Grant: Up to $500,000 inclusive of IDC/ 1-2 years |  |
| Cure Prize: Up to $1,000,000 inclusive of IDC/ 2-3 years |  |

1. Curebound Scientific Pillars

*Please indicate any of the following 5 research pillars that this proposal closely aligns with. Can select multiple pillars.*

|  |  |
| --- | --- |
| Prevention & Diagnostic Tools |  |
| Cancer Equities |  |
| Novel Therapeutics & Platforms |  |
| Immunotherapies & Personalized Vaccines |  |
| Pediatric Cancers |  |

***Part 6 of the LOI (Research statement) follows on the next page.***

1. Letter of Intent (Specific Aims Page) (1 page maximum)

* Describe the research project: briefly summarize the research aims, significance, approach, and impact
* Citations only may be included on a 2nd page
* Do not include confidential or proprietary information

1. NIH-style biosketch for Team Leader
2. NIH-style bio sketch for Team Leader

|  |
| --- |
|  |

Thank you for your interest in Curebound. We look forward to reviewing your LOI and will be in touch with you on June 12, 2023.